ERBB2 and gastric cancer: Growth of the HER2+ gastric cancer PDX in NOD/Shi-scid/IL-2Rγnull (NOG) mice was partially sensitive to single treatments with either SAL003 or Trastuzumab, but it became highly susceptible to combined treatments (Fig. 6a).